GANX
Gain Therapeutics, Inc. Common StockstockNASDAQ
gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.08 | 2026-11-10 | +12.04% | 3.826 |
| 1M | 1.26 | 2026-10-16 | -3.97% | 2.130 |
| 3M | 2.04 | 2026-08-17 | -40.69% | 2.253 |
| 6M | 1.62 | 2026-05-18 | -25.31% | 2.323 |
| 1Y | 2.82 | 2025-11-17 | -57.09% | 1.746 |
| 2Y | 1.69 | 2024-11-18 | -28.40% | — |
| 5Y | 9.24 | 2021-11-17 | -86.91% | 1.149 |
Gain Therapeutics, Inc. Common Stock (NASDAQ:GANX) stock price today is $1.21, and today's volume is 1,729,444. GANX is up 28.696% today. The 30 day average volume is 536,013. GANX market cap is $53.88M with 44.53M shares outstanding.